Skip to content
OpenCapital
Get started

Spyre Therapeutics, Inc. SYRE Trading assets

Trading assets at other companies

Biogen logo
BiogenBIIB
——

Other financials

Income statement

See full
Revenue-—
Operating income-$45.6M+14.8%
Net income-$69.0M-54.1%
EPS (diluted)-$0.74-23.3%

Balance sheet

See full
Cash & equivalents$97.2M+100%
Total debt$4.3M-9.6%
Total equity$670.8M+39.0%
Total assets$764.0M+34.1%

Cash flow

See full
Operating cash flow-$57.4M-40.0%
CapEx-—
Free cash flow-$39.4M-26.8%

Valuation

See full
Market cap$7.67B+307%

Profitability

See full
Operating margin-39,428.9%-49,795pp
Net margin-52,939.7%-61,871pp
FCF margin-3,442.8%-3,807pp

Returns & leverage

See full
Return on equity-31.1%-10.7pp
Debt / equity0.1×+0.1×
Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s trading assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s trading assets?
Spyre Therapeutics, Inc. (SYRE) reported trading assets of $419.2M in Q1 2026.
How has Spyre Therapeutics, Inc.'s trading assets changed year-over-year?
Spyre Therapeutics, Inc.'s trading assets increased by 14.2% year-over-year, from $367.11M to $419.2M.
What is the long-term trend for Spyre Therapeutics, Inc.'s trading assets?
Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s trading assets has grown at a 176.5% compound annual growth rate (CAGR), from $20.85M to $440.9M.
What does trading assets mean?
Securities and other financial instruments held for short-term trading purposes, measured at fair value with changes flowing through the income statement.